Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,rttnews·Jul 28 at 03:30 AMSLN-5.21%LH-2.53%
Amylyx Chief Legal Officer Gina Mazzariello sells USD 539,362 of common stockPUBT·Jul 13 at 03:01 PMAMLX-5.16%
10:31 ETPost-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsightprnewswire·Jul 7 at 09:32 AMAMLX-5.16%4547
Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?Simplywall·Jul 7 at 03:12 AMAMLX-5.16%
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire·Jul 3 at 11:15 AMAMLX-5.16%
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?Simplywall·Jun 27 at 11:09 AMAMLX-5.16%
Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114PUBT·Jun 23 at 06:00 AMAMLX-5.16%
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take ShapeMarket Beat·Jun 10 at 05:12 PMAMLX-5.16%
HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)Simplywall·May 28 at 04:26 PMAMLX-5.16%XLV-1.59%
LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)Tip Ranks·May 16 at 09:36 AMAMLX-5.16%FBT-3.63%
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation | AMLX Stock NewsStockTitan·May 15 at 03:15 AMAMLX-5.16%LABU-9.24%
